Depression is a highly prevalent risk factor for incident coronary heart disease (CHD) and for
cardiovascular morbidity and mortality in patients with established CHD. Several biological …

Dual antiplatelet therapy with aspirin and a P2Y12 receptor blocker is a key strategy to
reduce platelet reactivity and to prevent thrombotic events in patients treated with …

We review point-of-care (POC) diagnostics, in vitro diagnostic (IVD) tests that do not involve
the use of laboratory staff and facilities to provide the result. The analytical “targets” include …

Content Clopidogrel, one of the most commonly prescribed medications, is a prodrug
requiring CYP450 biotransformation. Data suggest its pharmacologic effect varies based on …

See also Machin SJ, Briggs C. Mean platelet volume: a quick, easy determinant of
thrombotic risk? This issue, pp 146–7. Summary. Aim: To determine whether an association …

The addition of clopidogrel to aspirin treatment reduces ischemic events in a wide range of
patients with cardiovascular disease. However, recurrent ischemic event occurrence during …

Background Pharmacogenetic determinants of the response of patients to clopidogrel
contribute to variability in the biologic antiplatelet activity of the drug. The effect of these …

Guideline recommendations on the use of dual antiplatelet therapy (DAPT) in patients with
acute coronary syndromes and in those undergoing percutaneous coronary intervention …

Background—The cytochrome P450 (CYP) 2C19 isoenzyme plays an important role in
clopidogrel metabolization. A recently explored CYP2C19* 17 allelic variant has been linked …

Context High residual platelet reactivity (HRPR) in patients receiving clopidogrel has been
associated with high risk of ischemic events after percutaneous coronary intervention (PCI) …